ClinicalTrials.gg
RecruitingNCT05881798Updated Nov 12, 2026

Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study

An observational study in Deep Vein Thrombosis, Venous Thromboembolism and Pulmonary Embolism, sponsored by Cook Research Incorporated. Recruiting at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Cook Research Incorporated (part of Cook Group Incorporated) · Observational

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
82
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies in Venous Thrombosis with a site in Spain — 3 open to participants now, 4 under way, 1 of them phase 3. Venous Thrombosis · Spain.

Planned enrollment
10th of 11
82 · median 528
Started
2025
with 2 others
Observational
11 of 43
2 open now
Registered
40th of 43
by date

Among the 43 studies in Venous Thrombosis with a site in Spain, this one is the 10th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2025, is one of 11 observational ones, and was the 40th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

3 of the 43 studies in Venous Thrombosis with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Venous Thrombosis with a site in Spain, or all of them as a file.
02

Study summary

This prospective, observational, post-market study will be performed to collect patient-level data on the Celect Platinum Vena Cava Filter Sets and the Günther Tulip Vena Cava Filter Retrieval Set to confirm continued safety and performance of the devices throughout their expected lifetime and continued acceptability of the benefit:risk ratio. Additionally, the study intends to evaluate longer-term (i.e., up to 5 years) outcome data while the filter is indwelling.

03

Conditions studied

  • Deep Vein Thrombosis
  • Venous Thromboembolism
  • Pulmonary Embolism

Keywords

  • Celect Platinum Vena Cava Filter
  • Gunther Tulip Vena Cava Filter Retrieval Set
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

A patient dataset is deemed suitable for inclusion in the study if the patient has a procedure where a Celect Platinum Vena Cava Filter

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A patient dataset is deemed suitable for inclusion if the patient has a procedure where a Celect Platinum Vena Cava Filter is placed
  • Subject has not previously participated in the Cook MDR-2126 study.

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded from enrollment if the patient or his/her legally authorized representative objects to collection and processing of his/her data or is not willing to sign the .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
82 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Patients indicated for the placement of a Celect Platinum Vena Cava Filter

    Patients indicated for the placement of a Celect Platinum Vena Cava Filter

    Device: Celect Platinum Vena Cava Filter

Interventions

  • DeviceCelect Platinum Vena Cava Filter

    Inferior vena cava filter

06

What researchers measure

Primary outcomes

  1. Filter-related primary endpoint (safety)

    Freedom from major adverse events through 12 months (365 ± 30 days), defined as clinically significant IVC penetration, migration of filter (\>2 cm)/filter components, filter fracture, embolization of filter or filter fragments to the heart or lungs, IVC thrombotic occlusion, symptomatic deep vein thrombosis while a filter is indwelling, access site complications with clinical sequelae, and procedure/device-related death.

    Time frame: Index procedure through 12-months post procedure

  2. Filter-related primary endpoint (performance)

    Performance: Technical placement success and freedom from symptomatic PE while a filter is indwelling through 12 months (365 ± 30 days).These values will be reported as aggregate. Technical placement success - Deployment of filter in a location suitable to provide sufficient mechanical protection against PE with no filter deformation, fracture, premature release, or clinical migration.

    Time frame: 12-months post procedure

  3. Filter Retrieval-related primary endpoint

    Freedom from major adverse events through 30 days post-procedure, defined as access site complications with clinical sequelae, and procedure/device-related death.

    Time frame: Through 30-days post procedure

  4. Filter Retrieval-related primary endpoint

    Technical retrieval success, defined as endovascular retrieval of complete filter.

    Time frame: At the time of retrieval procedure

07

Study locations

7 of 7 sites recruiting
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
    Recruiting
  • Hospital Universitari de Bellvitage
    Barcelona, 08907, Spain
    Recruiting
  • Hospital Reina Sofia de Cordoba
    Córdoba, 14004, Spain
    Recruiting
  • Parc Tauli
    Sabadell, 08208, Spain
    Recruiting
  • Leeds Teaching Hospital NHS Trust
    Leeds, West Yorkshire LS1 3EX, United Kingdom
    Recruiting
  • Hull University Teaching Hospitals NHS Trust
    Hull, HU3 2JZ, United Kingdom
    Recruiting
  • Royal Liverpool Hospital
    Liverpool, L7 8XP, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Cook Research Incorporated (CRI) is fully committed to supporting the principles of responsible data sharing, including providing qualified scientific researchers access to deidentified, patient-level data from CRI clinical studies to conduct legitimate scientific research. Data underlying the results reported in this clinical study will be made available for request immediately after approval or clearance of the product and ending 5 years after approval or clearance. Interested researchers may review the "Cook Research Incorporated Policy on Access to Clinical Study Data" at https://www.cookresearchinc.com/extranet/data-access.html and submit a complete research proposal to request data access. Additional study documents (such as the study protocol) will be shared as needed if the data access request is granted. A data sharing agreement will be executed for access to deidentified patient-level data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2027, 28 months after the start.

Of 127 observational studies under Venous Thrombosis, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 82. This study's planned 28 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2026 → Oct 2027 and completion Dec 2030 → Dec 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2023
First posted
May 31, 2023
StartActual
Jun 2, 2025
Primary completionEst.
Oct 2027was Oct 2026
CompletionEst.
Dec 2031was Dec 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Oct 2027
Nov 12, 2026
Study completion
Dec 2030→Dec 2031
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Oct 2026→Oct 2027
    Study completion Dec 2030→Dec 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05881798
Responsible party
Sponsor
First posted
May 31, 2023
Start date
Jun 2, 2025
Primary completion
Oct 2027 (estimated)
Completion
Dec 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Sabina Andersen
Contact
sabina.hjorth@cookmedical.com
+45 29 73 41 34

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion